Spartalizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Spartalizumab
Accession Number
DB14892
Type
Biotech
Groups
Investigational
Description

Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).

Synonyms
Not Available
External IDs
PDR001
Categories
Not Available
UNII
QOG25L6Z8Z
CAS number
1935694-88-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Spartalizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentRenal Cell Adenocarcinoma1
0RecruitingTreatmentTumors, Solid1
1Active Not RecruitingTreatmentAdvanced Solid Tumors / Advanced Solid Tumors, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Endometrial Cancer, Anaplastic Thyroid Cancer / Cancer, Anaplastic Thyroid / Chordoma and Alveolar Soft Part Sarcoma / Endometrial Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Triple Negative Breast Cancer (TNBC)1
1Active Not RecruitingTreatmentColorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma / Colorectal Cancers / Non-small Cell Lung Cancer (Adenocarcinoma) / Triple Negative Breast Cancer (TNBC)1
1Active Not RecruitingTreatmentGlioblastoma Multiforme (GBM)1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1Active Not RecruitingTreatmentSolid Tumors and Lymphomas1
1CompletedTreatmentAdvanced Malignancies1
1CompletedTreatmentHepatocellular,Carcinoma1
1CompletedTreatmentMalignant Lymphomas / Tumors, Solid1
1CompletedTreatmentMetastatic Colorectal Cancer (MCRC)1
1CompletedTreatmentMultiple Myeloma (MM)1
1Not Yet RecruitingTreatmentAgnogenic Myeloid Metaplasia / PMF / Post Essential Thrombocythaemia Myelofibrosis / Post Polycythemia Vera Myelofibrosis / Primary Myelofibrosis1
1Not Yet RecruitingTreatmentBRAF V600 Colorectal Cancer1
1RecruitingTreatmentAdvanced Solid Tumors1
1RecruitingTreatmentBRAF Mutant Colorectal Cancer / Cervical Squamous Cell Cancer / Esophageal Squamous Cell Cancer / Head and Neck Squamous Cell Cancer / Lung Squamous Cell Cancer / Malignant Neoplasm of Pancreas / Melanoma / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentBone Marrow Diseases / Hematologic Diseases / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndrome / Myelodysplastic Syndromes / Myeloid Leukemias1
1RecruitingTreatmentBreast Cancer / Colorectal Cancers / Hepatocellular Cancer / Lung Cancers / Malignant Neoplasm of Pancreas / Prostate Cancer / Renal Cancers1
1RecruitingTreatmentColorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma1
1RecruitingTreatmentColorectal Cancers / Esophageal SCC / Gastrointestinal Stromal Tumors / Head and Neck Squamous Cell Carcinoma (HNSCC) / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentHER2 Negative Breast Cancer / HER2-Negative Breast Cancer / Metastatic Epithelial Ovarian Cancer / Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Melanoma of Skin / Metastatic and Advanced Solid Tumors / Renal Cell Adenocarcinoma1
1RecruitingTreatmentIn Escalation: All Patients With Solid Tumors and Lymphoma / In Expansion: Melanoma1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Microsatellite Stable Colorectal Cancer / Nasopharyngeal Carcinoma / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Other Solid Tumors / Ovarian Cancer1
1RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentMetastatic Colorectal Cancer (MCRC)1
1WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma1
1, 2Active Not RecruitingTreatmentAdvanced Hepatocellular Carcinoma1
1, 2Active Not RecruitingTreatmentAdvanced Solid Tumors1
1, 2Active Not RecruitingTreatmentCancer, Anaplastic Thyroid / Lung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Other Solid Tumors / Triple Negative Breast Cancer (TNBC)1
1, 2Active Not RecruitingTreatmentCarcinoma, Pancreatic / Endometrial Carcinoma / Melanoma / Triple Negative Breast Cancer (TNBC)1
1, 2CompletedTreatmentHCC / Solid Malignancies1
1, 2RecruitingTreatmentAdvanced Malignancies1
1, 2RecruitingTreatmentAdvanced Solid Tumors1
1, 2RecruitingTreatmentGastrointestinal Stromal Tumors1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Stage IV Pancreatic Cancer AJCC v81
2Active Not RecruitingTreatmentAdenocarcinoma Of Esophagus / Adenocarcinoma of the Ovaries / Advanced Well-differentiated Neuroendocrine Tumors / Castration Resistant Prostate Adenocarcinoma / Gastric Adenocarcinoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Small Cell Lung Cancer (SCLC) / Soft Tissue Sarcoma (STS)1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentPoorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma / Well-differentiated Non-functional NET of Gastrointestinal Origin / Well-differentiated Non-functional NET of Pancreatic Origin / Well-differentiated Non-functional NET of Thoracic Origin1
2Active Not RecruitingTreatmentTriple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC)1
2Not Yet RecruitingTreatmentHistologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentMetastatic Pancreatic Ductal Adenocarcinoma1
2Not Yet RecruitingTreatmentStage III NSCLC1
2RecruitingTreatmentDLBCL, Diffused Large B Cell Lymphoma / Head and Neck Carcinoma / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Melanoma / MSS, Microsatellite Stable Colon Cancer / RCC, Renal Cell Cancer / TNBC, Triple Negative Breast Cancer / Urothelial Cancer1
2RecruitingTreatmentImmunotherapy / Lung Cancer Metastatic / Malignancies1
2RecruitingTreatmentMalignant Neoplasm of Stomach1
2RecruitingTreatmentMetastatic Colorectal Cancer (MCRC)1
2RecruitingTreatmentNasopharyngeal Carcinoma1
2RecruitingTreatmentPathologic Stage IIIB Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 / Pathologic Stage IIID Cutaneous Melanoma AJCC v81
2SuspendedTreatmentMelanoma1
3Active Not RecruitingTreatmentMelanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:33 / Updated on March 01, 2020 21:58

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates